QDEL Q1 Earnings Call: Cost Savings and Tariff Mitigation Anchor 2025 Outlook
Is now the time to buy QDEL? Find out in our full research report (it's free).
Revenue: $692.8 million vs analyst estimates of $689.8 million (2.6% year-on-year decline, in line)
Adjusted EPS: $0.74 vs analyst estimates of $0.59 (24.9% beat)
Adjusted EBITDA: $159.8 million vs analyst estimates of $149.4 million (23.1% margin, 7% beat)
The company reconfirmed its revenue guidance for the full year of $2.71 billion at the midpoint
Management reiterated its full-year Adjusted EPS guidance of $2.32 at the midpoint
EBITDA guidance for the full year is $595 million at the midpoint, in line with analyst expectations
Operating Margin: 4.7%, up from -247% in the same quarter last year
Market Capitalization: $2.09 billion
QuidelOrtho's first quarter results were shaped by growth in its core laboratories segment, stable immunohematology performance, and a robust flu testing season, offset by lower COVID-related and donor screening revenues. CEO Brian Blaser highlighted that the labs business, now over half of total revenue, delivered 7% year-over-year growth, while immunohematology grew 4%. Blaser credited the company's ongoing cost reduction initiatives—including staffing cuts and procurement efficiencies—for a 450 basis point improvement in adjusted EBITDA margin. The company also benefited from increased sales of its COVID-flu combination tests, which Blaser described as showing 'very stable performance,' helping mitigate the broader decline in COVID-only testing volumes. Management characterized the quarter as further evidence that its 2024 operational changes are positively impacting profitability and business stability.
Looking ahead, QuidelOrtho's management sees its narrowed set of strategic priorities—expanding platform content, margin improvement, and targeted commercial execution—as key drivers for 2025. Blaser emphasized the company's plans to fully offset anticipated tariff headwinds, noting, 'We believe the incremental actions we are taking are sufficient to fully offset the tariff impacts as they stand today.' The company expects recurring revenues from consumables to underpin stability, supported by a diversified manufacturing footprint. CFO Joe Busky added that visibility into labs and immunohematology growth in China supports a mid- to high-single-digit outlook for that market, assuming the tariff environment remains unchanged. Management remains focused on delivering cost savings and maintaining profitability targets, while monitoring for potential shifts in COVID and flu testing demand.
Management attributed the quarter's performance to solid growth in non-COVID segments, benefits from prior cost-reduction actions, and strong execution in the labs and flu testing businesses.
Labs business momentum: Core laboratories led growth, with consistent demand in clinical chemistry and immunoassay testing, representing over half of Q1 revenue.
Immunohematology stability: The immunohematology segment maintained its global leadership with steady 4% growth, particularly benefiting from strength in the Europe, Middle East, and Africa region.
Flu and combo testing resilience: Sales of flu tests and the COVID-flu combination test remained strong, offsetting the expected decline in pure COVID testing. The durability of the combo product contributed to recurring revenue streams.
Cost savings initiatives: Operational changes—including staff reductions, procurement efficiencies, and expense controls—were credited with expanding non-GAAP margins and reducing operating costs. Management expects further incremental savings in 2025.
Tariff mitigation efforts: The company outlined a multi-pronged strategy to counter expected $30–40 million tariff headwinds. Actions include re-sourcing materials, adjusting supply chains, selective pricing, and ongoing inventory repositioning. Management stated these steps are expected to fully neutralize tariff effects on financial results.
QuidelOrtho's outlook for 2025 is anchored by recurring revenue growth in core segments, ongoing cost control, and strategies to manage external headwinds such as tariffs.
Recurring consumables revenue: Management highlighted that over 90% of sales stem from consumables, providing a stable revenue foundation less susceptible to one-time instrument sales volatility. The company expects this model to drive consistent growth, especially in labs and immunohematology.
Cost discipline and savings: The company is on track to realize the remainder of its $100 million annualized cost savings program, with additional procurement and cash flow initiatives expected to deliver a further $30–50 million in savings during 2025. These efforts are intended to support margin expansion even as the company faces external cost pressures.
Tariff and macro environment management: Expected tariff headwinds are being addressed through supply chain adjustments, selective price increases, and cost reductions. Management expressed confidence that these measures will allow QuidelOrtho to maintain its guidance even if the tariff situation evolves, but noted that ongoing monitoring is required due to the dynamic nature of global trade policy.
In the coming quarters, the StockStory team will be watching (1) the pace at which cost savings and procurement initiatives translate into sustained margin gains, (2) the impact of tariff mitigation actions on both supply chain flexibility and pricing power, and (3) any changes in demand for respiratory testing—particularly the COVID-flu combination test. Progress on Savanna respiratory panel submission and broader product pipeline developments will also serve as key signposts for tracking execution.
QuidelOrtho currently trades at a forward P/E ratio of 12.1×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
26 minutes ago
- Politico
Will feds weigh in on religious vax carveouts?
Driving the Day RELIGIOUS VAX EXEMPTIONS — It's back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states' exemptions to vaccine mandates for school entry are gearing up for a fight, Lauren reports. Vaccine skeptics have sought to make their case to the Trump administration's Religious Liberty Commission — created by executive order in May — for executive action to bolster religious carve-outs. But they face pushback from public health experts who warn that more exemptions could threaten public health, setting up another front in the vaccine wars. Four states — California, Connecticut, Maine and New York — don't offer religious exemptions to school vaccine requirements, and Massachusetts lawmakers are considering banning them. West Virginia provides exemptions after GOP Gov. Patrick Morrisey signed an executive order earlier this year invoking the state's religious freedom law. Some religious liberty groups have called on the federal government — which has no say in state vaccine mandates — to use federal education funding as leverage to expand religious opt-outs from school immunization requirements, pointing to a Clinton-era religious protection statute. Precedential web: Some vaccine law experts question how far the executive branch could go to nudge those outlier states toward accepting religious exemptions. The Supreme Court curtailed the Religious Freedom Restoration Act's application to the states in 1997, and administrative conditions on federal funding can't run afoul of Congress' directions. But proponents say those lawyers ignore more recent opinions that work in exemption advocates' favor, pointing to a Covid-19-era decision lifting in-home gathering restrictions on religious grounds and, more recently, the court's ruling in favor of parents who want to opt their children out of LGBTQ+-themed lessons in public schools. Shifting winds: The number of kindergarteners entering school with at least one vaccine exemption continues to tick up, with the CDC reporting last week that 3.6 percent had one in the 2024-2025 school year, compared with 2.2 percent a decade ago. Days before the updated data was released, the American Academy of Pediatrics reaffirmed its opposition to religious exemptions, arguing they should be abolished to protect public health. 'In practice, nonmedical exceptions based on religious belief can substantially limit the public health value of vaccine requirements for school attendance,' the group said in a statement. 'There is no practicable way for schools or other involved community partners to distinguish fairly among religious or other nonmedical claims.' What's next: The Religious Liberty Commission will hold a hearing next month on public education issues, giving exemption proponents another opening to make their case. It's unclear where the White House stands on the concept — a spokesperson didn't comment — but the first Trump administration's HHS pursued avenues to grant health care workers expanded 'conscience' protections and to allow imports of certain vaccines due to some patients' religious beliefs. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. Your host is wondering whether concerns about a common allergy medicine's risks might catch the FDA's attention. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA NEW TOP LAWYER — FDA Commissioner Marty Makary named a longtime government attorney on Monday to be the agency's chief counsel, months after his first pick was torpedoed by Sen. Josh Hawley (R-Mo.). Sean Keveney, who most recently served as HHS's acting general counsel, served as a career civil servant at DOJ's civil rights division before becoming deputy general counsel at HHS in 2019, according to the department and his LinkedIn profile. His predecessor in the position, Hilary Perkins, was also a career DOJ lawyer whose appointment drew Hawley's ire before Makary's confirmation because of her record defending the Biden administration's abortion pill policies. While Perkins also defended the Trump FDA's mifepristone positions, that wasn't enough to overcome his opposition, and she ultimately stepped down days into the job. MDUFA KICKOFF — The FDA's medical device user fee program is not set to expire until Sept. 30, 2027, but the process to renew it has already begun. Despite HHS Secretary Robert F. Kennedy Jr.'s vocal distaste for the user fee programs, the Trump administration has made it clear they are committed to the monthslong process that will likely result in their renewal for another five years. Industry and FDA leaders — including FDA Commissioner Marty Makary and Center for Devices and Radiological Health Director Michelle Tarver — met Monday to discuss the potential sixth iteration of the medical device user fee program. 'While user fees support timeliness and predictability by providing FDA with additional resources, user fees are not a guarantee of approval,' AdvaMed's senior executive vice president, Janet Trunzo, said according to prepared remarks. 'They never have been, and they never should be.' In Congress SENATE PASSES FDA FUNDING — Before leaving town for the August recess, the Senate passed a bill to fund the FDA for fiscal 2026 as part of a minibus package by an 87-9 vote. The legislation, which funds the agency at $7 billion, is made up of $3.6 billion in taxpayer funds and $3.4 billion in user fee revenues. But it is unclear whether lawmakers will have to turn to a continuing resolution before government funding runs out at the end of September. The House Appropriations Committee previously advanced an FDA bill that funded the agency at a lower level. Research Corner BOOST FOR WOMEN'S HEALTH — The Gates Foundation said Monday it would spend $2.5 billion through 2030 to speed global women's research into maternal, menstrual, gynecological and sexual health. Pharma Moves Erika Sward is now chief advocacy officer at UsAgainstAlzheimer's. She previously was assistant vice president of national advocacy at the American Lung Association. Document Drawer FDA Commissioner Marty Makary met with Rep. John Joyce (R-Pa.) for an introductory meeting on July 24. He also met with People for the Ethical Treatment of Animals to discuss nonanimal testing approaches on July 21, according to newly posted public calendar disclosures. He also met with the leadership team of the Government Accountability Office on July 16 to discuss 'items of mutual interest.' WHAT WE'RE READING Top FDA cancer medicine regulator Richard Pazdur played a critical role in the rejection of Replimune Group's skin cancer therapy, STAT's Adam Feuerstein reports. Longevity companies are eyeing Montana as a potential hub for 'biohacking' treatments thanks to state laws embracing patients' 'right-to-try' experimental drugs, The Wall Street Journal's Alex Janin writes.
Newsweek
26 minutes ago
- Newsweek
Map Shows States Where COVID Is Rising
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. COVID-19 cases are reported to be rising in 27 states and "likely growing" in 12 states more as well as in Washington D.C., according to the latest data from the U.S. Centers for Disease Control and Prevention (CDC). The national health body warned that COVID-19 infections are estimated to be "growing or likely growing in 40 states [including D.C.], declining or likely declining in zero states, and not changing in nine states," as of July 29. "COVID-19 activity is increasing in many Mid-Atlantic, Southeast, Southern, and West Coast states," the CDC said on August 1. The percentage of positive cases is increasing nationally and while emergency department visits for COVID-19 are low, these visits are rising among all ages. "The current rise in COVID-19 cases is likely multifactorial," Dr. Steven Goldberg, primary care/urgent care physician and chief medical officer at HealthTrackRx—a PCR testing company that works with the CDC to help create fast testing for viruses including COVID-19— told Newsweek. He explained: "Increased summer travel, indoor gatherings due to high temperatures, waning vaccine immunity and the emergence of immune-evasive Omicron subvariants like KP.3 and LB.1 all play a role." "Wastewater surveillance, along with anecdotal reports of increased COVID-19–related ER and urgent care visits, corroborate this increase," Goldberg said. "Notably, real-time transmission estimates (Rt) show values above 1 in most states, indicating active spread." (Rt—the "effective reproduction number"—is an estimate of the average number of new infections caused by each infectious person.) The states with rising cases are each reported to have a more than 90 percent probability that the "COVID-19 epidemic is growing" there. The states with some of the highest probabilities include Florida (99.92 percent), Massachusetts (99.68 percent), Texas (99.52 percent) and Maryland (98.95 percent.) While the current summer wave of cases is less severe than previous peaks, "this surge may intensify further in the fall with back-to-school and return-to-office patterns unless mitigated by vaccine uptake and public awareness," Goldberg warned. The nine states where cases remain unchanged in recent days include Alaska, Hawaii, Idaho, Maine, Montana, Nevada, New Mexico, Rhode Island and Vermont. The percent of emergency department visits in these states was reported to be either low or very low, according to the CDC. According to Goldberg, several factors may explain the plateau in these nine states, including lower population density, such as in Montana and Alaska, as well limited large-scale indoor gatherings, and higher vaccine booster uptake. "It's also possible that regional Rt estimates are slightly lagging and may rise in future updates," he noted. The physician says updated vaccines targeting the latest Omicron sublineages, which are expected to emerge in the fall this year, are "essential" for combating rising cases and new variants. He said: "These next-generation vaccines are designed to enhance protection against immune-evasive strains like the Omicron-subvariants KP.3 and LB.1." Goldberg says that while reinstating broad health mandates may not be necessary at this stage, "targeted recommendations are prudent," noting that supporting voluntary masking in healthcare settings, airports, and high-risk indoor gatherings can help reduce transmission. He advises encouraging vaccination, especially for people at high risk as well as those living with high-risk individuals. Newsweek has contacted the CDC for comment via email and its online media contact form. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about COVID-19? Let us know via health@
Newsweek
2 hours ago
- Newsweek
Map Shows US Cities With Biggest House Price Declines Last Month
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A number of major metro areas saw dramatic list price declines in home prices last month as the U.S. housing market continues to deal with a cooling-off period after overheating that took place during a COVID-19 pandemic homebuying frenzy. The former pandemic boomtown of Austin, Texas, reported the biggest annual list price decline in the country last month and one of the highest shares of home listings with price cuts, according to data from Other top markets followed suit in annual declines as markets have become more balanced as inventory grows. Why It Matters Price corrections occur due to a number of factors, including fewer people relocating to areas. Home prices can be influenced by a variety of factors and can have a significant impact on the larger economy as they can affect consumer spending habits and be an indicator of economic growth. Where Prices Are Falling While home prices are still rising at the national level, the pace of this growth has slowed down significantly in recent months as sales have fallen and unsold homes have piled up in the market. In some parts of the country, the slowdown has been more significant. Recent data shows that the South and the West are shifting "decisively" in favor of buyers, writes, as the supply of for-sale homes in these regions increases and these properties spend more time on the market before going under contract—often with significant price cuts. By comparison, regions where the supply shortage is still acute—like the Northeast and the Midwest—are seeing less significant price changes. The metropolitan areas with the biggest year-over-year price decline in July were Austin (-4.9 percent), Miami (-4.7 percent), Chicago (-4.4 percent), Los Angeles (-4.2 percent), and Denver (-4 percent). In all of these cities with the exception of Chicago, the median list price was still above the national average of $439,450 last month. A typical home in Austin was listed for $510,950 in July. In Miami, $509,950. In Los Angeles, $1,148,483. And in Denver, $600,000. In Chicago, home costs are below the U.S. median list price, at an estimated $377,000. These cities also had some of the highest shares of listings with price cuts in the country. In Austin, 31.2 percent of listings had price reductions, and in Denver, 32.9 percent. Nationally, 20.6 percent of listings had price cuts. That means that the share of price cuts in Miami (17.7 percent), Chicago (15.4 percent), and Los Angeles (17.6 percent) was actually below the nationwide average. A map showing the top 10 U.S. metros with the biggest annual price declines in the country in July 2025 and the highest shares of price cuts. A map showing the top 10 U.S. metros with the biggest annual price declines in the country in July 2025 and the highest shares of price cuts. Behind These Numbers Austin saw an explosion in demand during the pandemic, when the rise of remote work allowed many out-of-state movers to relocate to the city. The Texas capital hardly had enough homes for everyone wishing to buy them then, and prices skyrocketed. At the same time, developers launched a construction boom that has since added many new homes to the city's supply. But demand has significantly diminished since the height of the pandemic, partially because of return-to-office orders and partially because of rising housing costs and historically elevated mortgage rates discouraging buyers. Austin found itself with a lot more new homes at a time when fewer people appeared ready to buy them. As a result, the city's housing market has been cooling down dramatically. The same is happening in Denver, another pandemic boomtown which is now seeing inventory piling up in its market. In these two cities, the median list price of a home in July was significantly lower than three years before, when higher mortgage rates put a halt to the pandemic homebuying frenzy. Home prices were 14.8 percent lower last month than in July 2022 in Austin, and 7.7 percent in Denver. The Miami housing market, though resilient, is also experiencing a correction after a period of rapid growth appreciation and tighter inventory. The median sale price of a home was a staggering 17.8 percent lower than three years earlier. But the other two cities in the top five lists of those experiencing the biggest annual price declines last month tell a different story. In Chicago, the median list price of a home was 7.7 percent higher than in July 2022; in Los Angeles, it was 18.4 percent higher.
